CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← OKYO Pharma Ltd (OKYO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

OKYO Pharma Ltd (OKYO)

Biological Products, (No Diagnostic Substances) · market cap $70M · as of 2026-07-15

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
OKYO Pharma Ltd (OKYO) is a micro-cap clinical-stage biotech with 4 employees and a market cap of approximately $82M, focused on a single lead asset, OK-101, currently in Phase 2 development for Dry Eye Disease. The company has an upcoming earnings catalyst on 2026-07-17 and three analyst price targets ranging from $7 to $13, implying significant upside versus the current ~$1.58 share price if the program succeeds. Key financial details including cash position, runway, and dilution history are not disclosed in available data, though dilution risk is flagged as elevated at 24%.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
OK-101Phase 2Dry Eye Disease
Price & technical context
3-month
-14.0%
6-month
-19.9%
12-month
-35.5%
52-wk range
$1.29–$3.11
vs 50-day MA
-13.9%
vs 200-day MA
-24.1%
Realized vol
75.3%
Max drawdown
-60.6%

Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for OKYO (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.